Images List Premium Download Classic

Histidine

Histidine-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Evaluating method, evaluating apparatus, evaluating program product, evaluating system, and terminal apparatus
Ajinomoto Co., Inc.
January 18, 2018 - N°20180017545

An evaluating method includes an evaluating step of evaluating a future risk of relapse of ulcerative colitis for a subject to be evaluated having ulcerative colitis in a remission phase using a concentration value of histidine, albumin, hemoglobin, or glutamic acid in blood of the subject.
Polypeptides
Vhsquared Limited
January 11, 2018 - N°20180009881

There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (cdr1-cdr3) and four framework regions, wherein: (a) at least one lysine residue in cdr1, cdr2 and/or cdr3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in cdr1, cdr2 and/or cdr3 ...
Targeted gas-filled microvesicles formulation
Bracco Suisse S.a.
January 11, 2018 - N°20180008731

Suspension of gas-filled microvesicles comprising a targeting ligand for binding to kdr or vegf/kdr complex. The suspension is obtained by reconstituting a freeze-dried residue with a carbohydrate-containing solution in the presence of a physiologically acceptable gas and is stabilized by the presence of histidine.
Histidine Patent Pack
Download + patent application PDFs
Histidine Patent Applications
Download + Histidine-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Histidine-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Neisseria meningitidis compositions and methods thereof
Pfizer Inc.
January 04, 2018 - N°20180000923

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in seq id no: 1 and a second polypeptide having the sequence set forth in seq id no: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in seq id ...
Insulin analogues with selective signaling properties and reduced mitogenicity
Case Western Reserve University
December 28, 2017 - N°20170369548

A two-chain insulin analogue contains aspartic acid at position b10 and penta-fluoro-phenylalanine at position b24, optionally histidine or glutamic acid at position a8, optionally additional substitutions or modifications at positions a13 and/or a14 and/or b28 and/or b29. The analogue may be an analogue of a mammalian insulin, such as human insulin, may optionally include (i) n-terminal deletion ...
Non-human animals expressing ph-sensitive immunoglobulin sequences
Regeneron Pharmaceuticals, Inc.
December 28, 2017 - N°20170367308

Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising ...
Histidine Patent Pack
Download + patent application PDFs
Histidine Patent Applications
Download + Histidine-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Histidine-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Long-acting insulin analogue preparations in insoluble and crystalline forms
Case Western Reserve University
December 21, 2017 - N°20170360895

A pharmaceutical formulation comprises an insulin analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof contains an insulin a-chain sequence that contains paired histidine substitutions at a4 and a8, and optionally a substitution at a21. The formulation further contains a pharmaceutically acceptable buffer containing at least about 4 zinc ions per 6 insulin analogue ...
Factor ix polypeptide mutant, its uses and method for its production
Case Western Reserve University
December 14, 2017 - N°20170355973

Disclosed are a modified fix (factor ix) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified fix polypeptide; a nucleotide sequence coding for the modified fix polypeptide; and a method for producing the modified fix polypeptide.
Liquid pharmaceutical composition
Ares Trading S.a.
December 07, 2017 - N°20170348225

The present invention relates to novel liquid protein formulations, particularly arginine-free liquid pharmaceutical compositions of etanercept. The invention employs particular combinations and classes of buffer systems, tonicifiers, and sugar stabilisers, optionally alongside polar ionisable amino acids (e. G. Aspartic acid, glutamic acid, histidine, and lysine), to afford a viable and storable drug product.
Paste-like bleaching agent and method for gentle oxidative hair lightening
Henkel Ag & Co. Kgaa
November 30, 2017 - N°20170340553

A combination of at least one selected dicarboxylic acid having 2 to 10 carbon atoms, in combination with at least one amino acid, selected from arginine, lysine, histidine or at least one of the salts of these amino acids, form a bleaching paste in order to reduce the damage to keratinic fibres caused by an oxidative bleaching treatment.
Blonding agent and method for gentle oxidative hair lightening
Henkel Ag & Co. Kgaa
November 30, 2017 - N°20170340549

A combination of at least one select dicarboxylic acid having 2 to 10 carbon atoms, in combination with at least one amino acid, selected from arginine, lysine, histidine or at least one of the salts of these amino acids, are included in a blonding powder to reduce the damage caused to keratin fibers by an oxidative bleaching treatment.
Mutated immunoglobulin-binding polypeptides
Ge Healthcare Bioprocess R&d Ab
November 23, 2017 - N°20170334954

An fc-binding polypeptide of improved alkali stability, comprising a mutant of an fc-binding domain of staphylococcus protein a (spa), as defined by seq id no: 1, seq id no: 2, seq id no:3, seq id no: 4, seq id no: 5, seq id no:6, seq id no:7, seq id no:22, seq id no 51 or seq id no 52 wherein at least the asparagine or serine ...
Use of halogen derivatives of histidine as electrolytic salt in a photovoltaic dye cell
Universite De Picardie Jules Verne
November 09, 2017 - N°20170323732

The invention relates to the use of halogenated histidine derivatives as electrolyte salts in the preparation of an electrolyte composition in a photoelectrochemical cell based on the sensitization to light of photoactive molecules, and also to a photoelectrochemical cell based on the sensitization to light of photoactive molecules comprising an electrolyte composition comprising at least one halogenated histidine derivative as ...
Histidine Patent Pack
Download + patent application PDFs
Histidine Patent Applications
Download + Histidine-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Histidine-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment for chronic kidney disease
Bio Health Solutions, Llc
November 09, 2017 - N°20170319528

A method of treating chronic kidney disease in a mammalian subject by administering a composition that includes l-arginine, glycine, l-glutamine, l-histidine, l-aspartic acid l-glutamic acid, and l-carnosine.
Methods of preparing peptides
Bio Health Solutions, Llc
November 02, 2017 - N°20170313740

The present invention provides methods of preparing a peptide having an n-terminal histidine, and compositions comprising a plurality of peptides prepared by the methods. The methods disclosed herein reduce racemization of the n-terminal histidine in the peptides during the synthesis process, thereby improving the yield and purity of the peptide compositions. Exemplary peptides that can be manufactured with the methods ...
Bispecific antibodies against cd3epsilon and bcma
Engmab Ag
October 26, 2017 - N°20170306036

A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human b cell maturation antigen (bcma) and human cd3epsilon, wherein the variable domains vl and vh in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain cl wherein the amino acid at ...
Process for synthesizing ergothioneine and related compounds
Engmab Ag
October 26, 2017 - N°20170305865

Or a physiologically acceptable salt, tautomer, stereoisomer or mixture of stereoisomers thereof. The process utilizes a n-benzyl protected histidine rather than the unprotected form of histidine. The process of the invention comprises the steps of: (a) deprotecting a n-benzyl protected histidine of formula 11 to form n-benzyl histidine of formula 12; (b) converting compound 12 to (s)-3-(1-benzyl-1h-imidazol-4-yl)-2...
Method for producing pure l-hercynine
Tetrahedron
October 05, 2017 - N°20170283382

The invention relates to a method for the purification of l-hercynine. Said method for the purification of l-hercynine, from a reaction mixture resulting from the reaction of l-histidine, in controlled ph conditions, with a methylating agent me x in a polar solvent or a mixture of polar solvents, at room temperature, is characterised in that it comprises at least one ...
Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of ...
Feldan Bio Inc.
September 21, 2017 - N°20170267728

The present description relates to synthetic peptides useful for increasing the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells. More specifically, the present description relates to synthetic peptides and polypeptide-based shuttle agents comprising an endosome leakage domain (eld) operably linked to a cell penetrating domain (cpd), or an eld operably linked to a histidine-rich domain and ...
Method for producing amino acid crystals and method for producing protein crystals
Feldan Bio Inc.
September 07, 2017 - N°20170253630

In the method, it is desirable that the amino acid contains at least one of alanine, arginine, asparagine, asparagine acid, cysteine, glutamine, glutamine acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and derivative of them.
Functionalization and purification of molecules by reversible group exchange
Illumina, Inc.
September 07, 2017 - N°20170253626

Embodiments of the present disclosure include methods and compositions for functionalizing molecules, such as oligonucleotides, with functional groups, including polyhistidine tags useful in affinity methods. Some embodiments include methods for modifying and purifying complex mixtures of molecules by exchange of functional tags.
Loading